Sellas Life Sciences Group

This study is for adults with acute myeloid leukemia (AML) who have achieved a second remission after their cancer returned. It compares a new immunotherapy called Galinpepimut-S (GPS) against the doctor's choice of standard available treatments. The main goal is to see if GPS he…